Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Since its introduction in 1988, recombinant human erythropoietin (epoetin) has been standard treatment for patients with anemia due to chronic kidney disease. From 1998 to 2004, nearly 200 epoetin-treated persons with chronic kidney disease developed antibodies to epoetin, resulting in pure red cell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bennett, Charles L., Cournoyer, Denis, Carson, Kenneth R., Rossert, Jerome, Luminari, Stefano, Evens, Andrew M., Locatelli, Francesco, Belknap, Steven M., McKoy, June M., Lyons, E. Alison, Kim, Benjamin, Sharma, Rishi, Costello, Stacey, Toffelmire, Edwin B., Wells, George A., Messner, Hans A., Yarnold, Paul R., Trifilio, Steven M., Raisch, Dennis W., Kuzel, Timothy M., Nissenson, Allen, Lim, Lay-Cheng, Tallman, Martin S., Casadevall, Nicole
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society of Hematology 2005
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895064/
https://ncbi.nlm.nih.gov/pubmed/16099877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-02-0508
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados